Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 11712039.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the case of a 43-year-old male patient with persistent multifocal, skin-restricted, CD30-positive, large T-cell lymphoma. Combination therapy of systemic interferon alfa and oral bexarotene was initiated on an experimental basis in the hope of circumventing therapies such as methotrexate, radiotherapy, or multiple-agent chemotherapy that may be required in such cases. This treatment was associated with rapid and marked regression of the patient's cutaneous lesions.
Medical subject headings
- Anticarcinogenic Agents
- Antineoplastic Agents
- Interferon-alpha
- Ki-1 Antigen
- Lymphoma, T-Cell, Cutaneous
- Skin Neoplasms
- Tetrahydronaphthalenes